Gates, Hopp back $110M megaround for CureVac's mRNA work
The Bill & Melinda Gates Foundation joined German billionaire Dietmar Hopp in a venture syndicate that is injecting a whopping $110 million of fresh funds into CureVac, a German mRNA biotech which has now garnered some $330 million in support.
CureVac turns to Cambridge, MA, to jump-start its mRNA pipeline
Germany's CureVac has launched a subsidiary in the biotech hotbed of Cambridge, MA, hoping to accelerate the development of its messenger RNA therapies on the heels of a major investment from the Bill and Melinda Gates Foundation.
The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.
Gates Foundation bets $52M on CureVac's mRNA promise
The Bill and Melinda Gates Foundation is throwing its weight behind CureVac, a German biotech working to transform patients' cells into drug factories, committing $52 million in hopes of developing vaccines for the developing world.
CureVac has made its second notable deal with Big Pharma this year, this time partnering with Boehringer Ingelheim to offer its investigational lung cancer vaccine in a $45 million deal with potential milestone payments of up to $556 million.
Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac
A little more than two months after inking a licensing deal with Sanofi, CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic vaccine aimed at lung cancer. The deal also includes up to about $556 million in prospective milestones for the German biotech.
Sanofi Pasteur taps CureVac for its RNA vaccine tech
Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.
Sanofi Pasteur and Germany's CureVac first joined up in 2011 with a licensing option agreement for a slew of pathogens. Now, they're beefing up their partnership with another licensing deal, this one giving the French company rights to a new mRNA-based vaccine.
When it comes to flu pandemics, making and distributing vaccines quickly is of utmost importance. And now German scientists have developed an RNA vaccine that could cut flu vaccine production time from months to weeks.
CureVac, a biotech company pushing therapeutic cancer vaccines into Phase IIb studies, landed a cool $104 million from German multibillionaire Dietmar Hopp's investment group, dievini Hopp BioTech Holding.